Podcasts about practicalities

  • 207PODCASTS
  • 345EPISODES
  • 50mAVG DURATION
  • 1WEEKLY EPISODE
  • Nov 1, 2022LATEST

POPULARITY

20152016201720182019202020212022


Best podcasts about practicalities

Latest podcast episodes about practicalities

Practical AI
The practicalities of releasing models

Practical AI

Play Episode Listen Later Nov 1, 2022 37:26


Recently Chris and Daniel briefly discussed the Open RAIL-M licensing and model releases on Hugging Face. In this episode, Daniel follows up on this topic based on some recent practical experience. Also included is a discussion about graph neural networks, message passing, and tweaking synthesized voices!

Low Tox Life
307. Hannah Churton - Food waste solutions from the mindset, to the practicalities of worm farming and compost

Low Tox Life

Play Episode Listen Later Oct 30, 2022 82:41


This week is all about taking action on food waste - which, if it was a country it would be the 3rd largest emitter behind China and the USA - It's a BIG deal and instead we seem to keep focusing on what's on the plate instead of what's in the BIN! Hannah Churton literally lives to make people feel confident about bringing worm farming or composting solutions into your life and in this show we discuss best options for a range of home styles - including apartments without balconies - and we also discuss barriers to entry, hiccups when getting started and common trouble shoots and what to do. I hope you love it as much as I did. I took extra good care of my worms this week, remembering just how important a job they did, after speaking with Hannah. Enjoy the show and head to the show notes for more details over at lowtoxlife.com/podcastSee omnystudio.com/listener for privacy information.

Centre for Christian Living podcast
Podcast episode 085: The practicalities of complementarianism with Jane Tooher

Centre for Christian Living podcast

Play Episode Listen Later Oct 30, 2022 31:36


Imagine being part of a church that wasn't confused, reluctant or reticent about complementarianism, but rather embraced it. Imagine being so convinced of what God says that you're able to express it confidently in what you say and do. Imagine being so compelled by the goodness of what God says that you express it positively in church life. This is the vision set forward in the new book, “Embracing Complementarianism” by Graham Beynon and Jane Tooher. In this episode of the CCL podcast, we consider the practicalities of complementarianism in our second episode with Priscilla & Aquila Centre Director and Moore College lecturer Jane Tooher on the matter. For an edited transcript and show notes, visit https://ccl.moore.edu.au/resources/podcast-episode-085/ To find out more about Jane and Graham's book, visit https://www.thegoodbook.com.au/embracing-complementarianism

Gardens, weeds and words
S03 Episode 5: Where the sun don't shine. With Susanna Grant

Gardens, weeds and words

Play Episode Listen Later Oct 26, 2022 50:27


A blend of slow radio, gardening advice and conversation, and readings from the best garden and wildlife writing.   These notes may contain affiliate links.        Garden soundtrack   The joys of October in the garden.     Reading from A breath from elsewhere, by Mirabel Osler 4:28 Read by Jemma Cooper   A breath from elsewhere, by Mirabel Osler. Bloomsbury, 1997. https://amzn.to/3Stlvr9     06:52 Gardening in the shade       08:10 Interview with Susanna Grant   08:20 First encounters   Wild about Weeds, by Jack Wallington https://amzn.to/3FbVU31   09:17 Sharing weeds (and weeds)   10:48 How the name – and the business – 'Linda' came about   12:35 A Jack of All Trades – Susanna's other work   16:11 A Fair Weather Shop   19:26 Susanna's childhood memories of plants and the natural world   Flower Fairy books, by Cicely Mary Barker https://www.amazon.co.uk/dp/B09PGM2YBD?binding=hardcover&searchxofy=true&ref_=dbs_s_bs_series_rwt_thcv&qid=1666786266&sr=1-19   Observer Book of Wild Flowers https://amzn.to/3SxxWCo   21:26 Arnold Circus and the Boundary Estate – the community garden   Radicle, edited by Sui Searle aka @decolonisethegarden https://radicle.substack.com   Volunteering: a problem and an opportunity? by Joanna Pidcock https://radicle.substack.com/p/volunteering-a-problem-and-an-opportunity   29:49 From Gardens Where We Feel Secure, by Susanna Grant and Rowan Spray, published by Rough Trade Books and The Garden Museum https://amzn.to/3Dpdrn4   35:31 Practicalities of window box gardening with perennials       ***   Thank you to Susanna Grant for giving up her time to talk to me about her creative nature-inspired practice.   Susanna's book Shade is published by Bloom, 2022, and is available here https://amzn.to/3F6eGsu   The Rough Trade/Garden Museum pamphlet by Susanna, with photography by Rowan Spray is From Gardens Where We Feel Secure, and is available here https://amzn.to/3Dpdrn4   Pamphlets in the same series, such as Horticultural Appropriation by Claire Ratinon and Sam Ayre, are also available here https://roughtradebooks.com/collections/editions   You can find Susanna on Instagram here https://www.instagram.com/hellotherelinda Or on her website: https://www.hellotherelinda.com/     My own book, To Stand and Stare; how to garden by doing next to nothing, will be published by DK Life on Feb 2, 2023, and is available to preorder here https://geni.us/Qs2d     I'm so grateful to Jemma Cooper for lending us her lovely tones for the reading from Mirabel Osler's A breath from elsewhere. You can find Jem on Instagram here https://www.instagram.com/thecountrynurse_   I'm ever appreciative of all my listeners for your continued support and reviews, I really do appreciate them. You can support the podcast by buying its producer a virtual cup of coffee for three quid, at https://ko-fi.com/andrewtimothyOB. Proceeds will go towards equipment, software and the monthly podcast hosting fees.    A year of garden coaching If you'd like to find out more about my my 12 month online garden coaching programme, please visit the website, where you can read more details. There will be a few spaces opening up early in the new year, so do sign up to be the first to hear when you can book. https://www.gardensweedsandwords.com/garden-coaching       website: gardensweedsandwords.com email: gardensweedsandwords@gmail.com Instagram: instagram.com/AndrewTimothyOB Twitter: twitter.com/AndrewTimothyOB 

Elder Health Connection
Aging Nervous System [034]

Elder Health Connection

Play Episode Listen Later Oct 24, 2022 15:49


Join Caroline for Part 3 of our “What is Aging?” series covering the nervous system. In this episode we give an overview of what is happening at the cellular level inside the nervous system as we age and the implications for learning and memory, as well as neurodegenerative conditions like Alzheimer's disease and Parkinson's disease.    Episodes on Aging:  Ep 32 - Aging Bones & Joints Ep 33 - Aging Muscles   Episodes on Brain Health:  Ep 28 - Integrative Brain Health with Dr. Andrew Wong Ep 22- Communication and Care Partners with Abbe Simon Ep 16 - Exercise for Your Heart and Brain with Laura Mesches Ep 6 - Parkinson's Practicalities with Nicole Reynolds Ep 2 - Dignity in Dementia Care with Anne Stankiewicz Ep 1 - Memory and Communication Across the Lifespan with Alicia White   Further Reading:  Todorova, V., & Blokland, A. (2016). Mitochondria and Synaptic Plasticity in the Mature and Aging Nervous System. Current Neuropharmacology, 15(1), 166–173. https://doi.org/10.2174/1570159x14666160414111821   Work with Caroline: Schedule an intro call: https://morrisclinicpt.janeapp.com https://carolinemorris.com 

The Modern Therapist's Survival Guide with Curt Widhalm and Katie Vernoy
How Therapists Can Really Help Kids Who Are Being Bullied

The Modern Therapist's Survival Guide with Curt Widhalm and Katie Vernoy

Play Episode Listen Later Oct 24, 2022 45:26


How Therapists Can Really Help Kids Who Are Being Bullied Curt and Katie chat about how therapists can support the targets of bullying. We explore what bullying actually is as well as what can be problematic in how it is typically addressed. We also discuss individual therapy strategies for kids who have been bullied. Curt and Katie also debate about whether the targets of bullying should change what makes them different to avoid getting bullied.     Transcripts for this episode will be available at mtsgpodcast.com! In this podcast episode we talk about how therapists can effectively treat bullying in therapy For Bullying Prevention month, we decided to dig into what bullying actually is and how therapists can treat bullying in therapy. What is bullying actually? The definition of bullying and how it is described currently (i.e., teasing versus bullying) Target and aggressor (versus victim and bully) as more appropriate language to describe participants Three essential elements of bullying: ongoing behavior, behavior is intended to be harmful, and there is a power differential between the aggressor and the target The relevance of impact versus intention of behavior Numerous types of power imbalances that can be present Types: physical, verbal, social or covert, cyber bullying What is problematic in how bullying is typically addressed? “Aggressors have a more robust set of social skills. And it's being able to adapt more quickly to things that are socially changing, even in the moment. This also plays a role in the reporting on the people teasing them because the more socially adept kids are then better able to convince the adults around them. Oh, no, we were just playing. We were teasing back and forth.” – Curt Widhalm, LMFT Most bullying is not observed by adults Not moving past holding space Looking toward community interventions rather than individual Lack of understanding of what cyber bullying actually looks like (when you haven't grown up as a digital native) Aggressors have a more robust set of social skills Strategies for kids who have been bullied “I think we also need to recognize that if we go too far in telling people not to be different, we are invalidating their identity. And if we don't go far enough, and we don't help them to be part of society, they may continue to get really harshly bullied, but either one is damaging.” – Katie Vernoy, LMFT Beyond ignoring (especially if there is an audience) Understanding what the target's response means to the aggressor Not playing into what the aggressor is doing, escalating to forceful “stop,” seeking out a trusted adult (or multiple adults) Debate on whether a target should shift their behavior and change what makes them different Building confidence versus masking Safety now versus identity development Practicing responses to potential bullying statements in session Including targets in the planning process with adults The challenges with mediation within school settings (and the importance of follow up) Systemic or prevention programs that also address bystanders Our Generous Sponsors for this episode of the Modern Therapist's Survival Guide: Thrizer Thrizer is a new modern billing platform for therapists that was built on the belief that therapy should be accessible AND clinicians should earn what they are worth. Their platform automatically gets clients reimbursed by their insurance after every session. Just by billing your clients through Thrizer, you can potentially save them hundreds every month, with no extra work on your end. Every time you bill a client through Thrizer, an insurance claim is automatically generated and sent directly to the client's insurance. From there, Thrizer provides concierge support to ensure clients get their reimbursement quickly, directly into their bank account. By eliminating reimbursement by check, confusion around benefits, and obscurity with reimbursement status, they allow your clients to focus on what actually matters rather than worrying about their money. It is very quick to get set up and it works great in completement with EHR systems. Their team is super helpful and responsive, and the founder is actually a long-time therapy client who grew frustrated with his reimbursement times The best part is you don't need to give up your rate. They charge a standard 3% payment processing fee! Thrizer lets you become more accessible while remaining in complete control of your practice. A better experience for your clients during therapy means higher retention. Money won't be the reason they quit on therapy. Sign up using bit.ly/moderntherapists if you want to test Thrizer completely risk free! Sign up for Thrizer with code 'moderntherapists' for 1 month of no credit card fees or payment processing fees! That's right - you will get one month of no payment processing fees, meaning you earn 100% of your cash rate during that time. Simplified SEO Consulting Have you spent countless hours trying to get your website just right and yet, it's not showing up on Google and it doesn't seem like anyone's able to find it? Simplified SEO Consulting has a unique solution. They've been training therapists to optimize their websites, so they show up better on Google for the past 4 years. But let's face it, with the busy schedules we all keep it can be hard to find the time to optimize your website even when you learn how. So, they are hosting a 16 day cruise in July 2023 going from LA to Hawaii and back. When you join them, you'll get intensive SEO education and coaching during the 10 days at sea. Most importantly, you'll have plenty of time to sit next to the pool and implement everything you've learned and then ask their team for feedback. Yes, it's the perfect excuse for a Hawaii vacation. But it's also a time to both learn about SEO and actually implement what you learn. The upcoming cruise is a unique opportunity to learn to optimize your own website, have time to practice what you learn and the ability to get feedback from leading SEO professionals in our field. To reserve your spot before it fills up, go to https://simplifiedseoconsulting.com/training-cruise-for-better-seo/  Resources for Modern Therapists mentioned in this Podcast Episode: We've pulled together resources mentioned in this episode and put together some handy-dandy links. Please note that some of the links below may be affiliate links, so if you purchase after clicking below, we may get a little bit of cash in our pockets. We thank you in advance! Article: Parent-Assisted Social Skills Training to Improve Friendships in Teens with Autism Spectrum Disorders Article: The 411 on Bullying Relevant Episodes of MTSG Podcast: Risk Factors for Suicide: What therapists should know when treating teens and adults The Practicalities of Gender Affirming Care for Trans Youth: An interview with Jordan Held, LCSW Working with Trans Clients: Trans resilience and gender euphoria – An interview with Beck Gee-Cohen Neurodivergence: An interview with Dr. Joel Schwartz   Who we are: Curt Widhalm, LMFT Curt Widhalm is in private practice in the Los Angeles area. He is the cofounder of the Therapy Reimagined conference, an Adjunct Professor at Pepperdine University and CSUN, a former Subject Matter Expert for the California Board of Behavioral Sciences, former CFO of the California Association of Marriage and Family Therapists, and a loving husband and father. He is 1/2 great person, 1/2 provocateur, and 1/2 geek, in that order. He dabbles in the dark art of making "dad jokes" and usually has a half-empty cup of coffee somewhere nearby. Learn more at: www.curtwidhalm.com Katie Vernoy, LMFT Katie Vernoy is a Licensed Marriage and Family Therapist, coach, and consultant supporting leaders, visionaries, executives, and helping professionals to create sustainable careers. Katie, with Curt, has developed workshops and a conference, Therapy Reimagined, to support therapists navigating through the modern challenges of this profession. Katie is also a former President of the California Association of Marriage and Family Therapists. In her spare time, Katie is secretly siphoning off Curt's youthful energy, so that she can take over the world. Learn more at: www.katievernoy.com A Quick Note: Our opinions are our own. We are only speaking for ourselves – except when we speak for each other, or over each other. We're working on it. Our guests are also only speaking for themselves and have their own opinions. We aren't trying to take their voice, and no one speaks for us either. Mostly because they don't want to, but hey. Stay in Touch with Curt, Katie, and the whole Therapy Reimagined #TherapyMovement: Patreon Buy Me A Coffee Podcast Homepage Therapy Reimagined Homepage Facebook Twitter Instagram YouTube   Consultation services with Curt Widhalm or Katie Vernoy: The Fifty-Minute Hour Connect with the Modern Therapist Community: Our Facebook Group – The Modern Therapists Group Modern Therapist's Survival Guide Creative Credits: Voice Over by DW McCann https://www.facebook.com/McCannDW/ Music by Crystal Grooms Mangano https://groomsymusic.com/

Faith Presbyterian Church
Additional Thoughts on the Fourth Commandment: Perspectives & Practicalities, Deuteronomy 5:6, 12-15

Faith Presbyterian Church

Play Episode Listen Later Oct 9, 2022


Pastor Nicoletti preaches an additional sermon on the fourth commandment.

Dream Dare Dazzle
Zesties 10: Practicalities of Insights

Dream Dare Dazzle

Play Episode Listen Later Oct 2, 2022 28:41


How do our insights translate into the practicalities of daily life?We certainly don't go around telling people I am 'no one' and I have nothing for obvious reasons. These realizations happen silently and subtly within our consciousness..As they do, you continue to play your role(s) as you have up to now. That doesn't mean being cold, separated or distant. It means outcomes matter less to you, people's words and behaviours no longer upset you. You are no longer motivated by acquiring 'things', you lose the neediness from your relationships. You start living from the inside out, instead of from the outside in......

Emilia Thompson PhD
Episode 152. Healthful fat loss, protein practicalities, the guilt of overeating and ‘feeling fat'.

Emilia Thompson PhD

Play Episode Listen Later Sep 21, 2022 50:35


In this episode, Georgia, Anna and Emilia answer client questions on what to do when dieting triggers binge behaviours, Brene Brown recommendations, scale weight changes, the frustration of sickness and self compassion, protein practicalities, sleep and fat loss, managing body conversations, training around injury, alternative medicines, protein brands, feeling like a failure when overeating and ‘feeling fat'. For more information, visit www.emilia.fitness or @emiliathompsonphd

Virtual Legality
Is The FTC REALLY on a Timer? | "Deadlines" and Microsoft x Activision (VL712)

Virtual Legality

Play Episode Listen Later Sep 9, 2022 19:43


Many, many folks are wondering just when we might hear more on the saga of Microsoft x Activision's regulatory review here in the US. Others are positing that the FTC is obligated to do something soon or stay silent forever more. The reality is considerably more complex. Let's discuss. When the government has the leverage a deadline is just a "deadline"...in Virtual Legality. CHECK OUT THE VIDEO AT: https://youtu.be/u0jxYJw7BJ8 #xbox #activision #sony *** WANT TO SUPPORT THE CHANNEL? UTREON - https://utreon.com/c/hoeglaw/ PATREON - https://www.patreon.com/VirtualLegality STORE - https://teespring.com/stores/hoeg-law-store BITCAST (Sundays 11AM Eastern) - https://www.youtube.com/channel/UCgHBXONMT06nX_8RZ5r32UA *** CHAPTERS 00:00 Introduction (Thanks, FalkusVipus) 01:25 An Overview of the Review Process 04:48 The Practicalities of Regulatory Dealings 13:51 Indefinite Settlements and Lack of Approval 17:42 Conclusion *** Discussed in this episode: PLAYLIST https://www.youtube.com/playlist?list=PL1zDCgJzZUy_vBs7Qt9-ROfumOtIrSdP8 VISUAL AID https://www.ftc.gov/sites/default/files/u269/hsr-timeline.png HSR SUMMARY https://www.ftc.gov/advice-guidance/competition-guidance/guide-antitrust-laws/mergers/premerger-notification-merger-review-process LAW AND REGULATIONS https://www.law.cornell.edu/uscode/text/15/18a https://www.ecfr.gov/current/title-16/chapter-I/subchapter-H/part-803 https://www.ecfr.gov/current/title-16/chapter-I/subchapter-H/part-803/section-803.3 FTC WARNING LETTER https://www.ftc.gov/enforcement/competition-matters/2021/08/adjusting-merger-review-deal-surge-merger-filings *** "Virtual Legality" is a continuing series discussing the law, video games, software, and everything digital, hosted by Richard Hoeg, of the Hoeg Law Business Law Firm (Hoeg Law). CHECK OUT THE REST OF VIRTUAL LEGALITY HERE: https://www.youtube.com/playlist?list=PL1zDCgJzZUy9YAU61GoW-00K0TJOGnPCo DISCUSSION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS LEGAL ADVICE. INDIVIDUALS INTERESTED IN THE LEGAL TOPICS DISCUSSED IN THIS VIDEO SHOULD CONSULT WITH THEIR OWN COUNSEL. *** Twitter: @hoeglaw Web: hoeglaw.com

Lexman Artificial
Ryan Schiller from the Vancouver Giants

Lexman Artificial

Play Episode Listen Later Sep 7, 2022 3:12


Ryan Schiller from the Vancouver Giants talks about his new team, the Cervelats, and how they're trying to make it in the league. He also discusses the challenges that come with playing in Quebec, and how the Giant players are adapting to the Canadian climates.

RCGP eLearning Podcast
The practicalities of flu vaccination

RCGP eLearning Podcast

Play Episode Listen Later Aug 23, 2022 8:44


The 2022/23 flu season is fast approaching, bringing with it all the usual questions about who gets which vaccine and how to best organise a vaccination programme. In this podcast, Dr Toni Hazell talks to Dr. Sally Higginbottom, author of our eLearning module on influenza. Sally will delve into some of the practicalities of running a successful vaccination programme including which vaccine for which patient, what to do if patients are concerned about egg allergy or have religious concerns and which vaccines can be given at the same time as the flu vaccination.  CSL Seqirus has funded this podcast and has been involved in discussion for the topic of the podcast. The content has been prepared independently by the RCGP without any input from CSL Seqirus. These podcasts are intended for healthcare professionals and are disseminated by media determined by the RCGP.

Luke Powell Daily Devotions
Prayer & Fasting (day 5): practicalities

Luke Powell Daily Devotions

Play Episode Listen Later Aug 12, 2022 3:49


Let's get practical about fasting! Fasting FOOD is the way to go, unless you have health issues that prevent it. Don't fall for the popular "fast from negativity, complaining, and anxiety" idea - that's not a fast at all. When you fast, you go without something good to rely more deeply on God. These devotions are free! Please consider supporting this ministry financially here: https://bit.ly/31Bh8p7 Become a patron to get a Saturday video devotion each week: https://www.patreon.com/lukepowell

Invisible India
76| Thriving as a Foreigner in India | Part 1 | Practicalities

Invisible India

Play Episode Listen Later Aug 2, 2022 18:22


What are the crucial elements you need to life life well in India? Part 1 of this 2 part episode deals with the practicalities of living in India as someone who didn't grow up there. Skip the outdated guide books and listen in to this advice from Jessica, who first started living in India in 2006. Negotiation, dealing with the complications of Indian currency, how to give and receive directions and of course tips on learning the local language(s) of the place you are visiting or living in. Whether you are visiting or planning on living in India, these tips will help you go beyond surviving to thriving in India with these tips! Links mentioned in this episode Download the Ultimate Hindi Learning Resource Guide for FREE It is a 21 page PDF including curated resources of Jessica's top recommendations of Indian owned businesses who are creating the best Hindi learning tools! The Guide Includes: -Ratings of Hindi teachers, top classes, programs and apps! -Contact information and discount codes for the best teachers and programs to learn Hindi! -Personal notes and recommendations on ways to learn Hindi through native speakers. -21 pages of Jessica's curated recommendations for teachers based on 16+ years of experience in learning Hindi Get it here! _____________________ Join our Patreon community for special content and perks! www.patreon.com/invisibleindia

The Connected Yoga Teacher Podcast
282: What's Missing? Yoga Class Notes with Kathryn Anne Flynn

The Connected Yoga Teacher Podcast

Play Episode Listen Later Jul 25, 2022 70:28


The Connected Yoga Teacher Podcast 282: What's Missing? Yoga Class Notes with Kathryn Anne Flynn   Description: Have you ever been to a yoga class and noticed that something is missing? Perhaps it was the cues given, or the postures practices, or even the sequence of the class. There are certain key elements that we need to have to make a well-rounded yoga class and we might be missing some of them! Kathryn Anne Flynn shares her expertise on this topic and how we can make our classes more accessible to all.   Kathryn Anne Flynn is a teacher and student of yoga, meditation, Ayurveda, and psychotherapy in Ottawa, Canada. She is known for weaving together her fields of study and practice tools to meet life with a compassionate presence. Students of many generations call her their teacher and they are drawn to her inclusivity and authenticity. Kathryn is also the host of the Intelligent Edge Yoga Podcast, author of Teach Kind, Clear Yoga, and offers online practices as well as trainings, workshops, and retreats.   Kathryn shares her insights about some of the key elements missing from yoga classes (especially with newer teachers) such as silence, little joint care, and music and playlists, and gives us tips on how we can effectively incorporate these into our yoga classes to become better teachers and create a better environment for our yoga students. This is a really motivating episode to get inspiration about how to improve on your classes and create a better environment for our yoga students.   Key Takeaways: [0:00] Shannon addresses the recent US Supreme Court decision to overturn Roe v Wade. [1:45] This episode is also sponsored by the Accessible Yoga Continuing Education Program. [8:33] Shannon introduces her guest for this episode - Kathryn Anne Flynn. [11:55] You can win one of Kathryn's books simply by leaving a comment in the show notes! [13:04] What does Kathryn do and who does she do it for? [14:37] What got Kathryn interested in her work around psychotherapy and trauma therapy, from being a yoga educator? [17:29] Kathryn is the author of Teach Kind, Clear Yoga. What was her motivation for writing the book and what feedback has she received about it? [19:31] There are often trends in things that are missing from new yoga teachers' classes. Kathryn reflects on how she made this observation. [22:14] A reminder for people going through their yoga teacher training: Teaching yoga is never going to be as hard as it is in your training. [24:01] Something that is often missing even from experienced teachers' classes is silence. [26:09] Another element often missing in yoga classes is little joint care. [28:53] There is value in simplicity and repetition. [32:33] A tip for new teachers - if you are nervous when teaching yoga, you can use music to support your teaching and create atmosphere in your classes. [33:54] Shannon pops in to share a conversation she had with Sara Villamil about OfferingTree. [36:11] Is music essential to a yoga class or can we teach without it? Shannon and Kathyrn share their perspectives. [43:07] Kathryn shares some tips around what to consider when sequencing your yoga class. [48:33] You can bring creativity into sequencing your yoga classes. [50:16] Kathryn developed her own personal style of yoga because of the communities she worked with and paying attention to their needs. [53:05] Kathryn highlights two types of postures that are often missing from yoga classes. [59:30] What are some final thoughts Kathryn has for a yoga teacher who is feeling like something is missing from their class? [60:39] Get Kathryn's book and connect with her via her website and social media. [62:24] Shannon shares her key takeaways from this interview with Kathryn. Links: Kathryn Anne Flynn Kathryn Anne Flynn on Instagram and Facebook Intelligent Edge Yoga Podcast Teach Kind, Clear Yoga by Kathryn Anne Flynn Accessible Yoga Continuing Education Program Accessible Yoga Podcast The Connected Yoga Teacher Podcast Episode 281: Yoga Teaching Tips with Gabrielle Harris Diane Liska Sara Villamil Self-Awakening Yoga, by Don Stapleton Aborsh Podcast Intelligent Edge Yoga Podcast - Yoga Playlists: The Effects of Music on Practice and the Practicalities of Teaching to Music on Apple and Spotify Balance Cushion The Connected Yoga Teacher Podcast Episode 268: Yoga for Surviors of Sexual Assault with Nikki Adams Pelvic Health Professionals Native Land Digital Shannon Crow on Instagram The Connected Yoga Teacher Facebook Group   Gratitude to our Sponsors, OfferingTree and Accessible Yoga Continuing Education Program. Quotes from this episode: "Teaching yoga is never going to be as hard as it is in your training."   "Reviewing your teaching can remain uncomfortable and it's worth it."   "If you design your classes in a way that folks are safe doing the practice, you can have faith in the resilience of the human body - which means you can have faith in the potency of silence and restrain yourself to offer more space because people need silence so badly if their lives are super busy and loud."   "I think it's important to be able to teach and practice both with and without [music]. It's just another tool that you need to know how and when to apply it."  

River City Grace Community Church
Prayer: Purposes, Pitfalls, and Practicalities

River City Grace Community Church

Play Episode Listen Later Jun 26, 2022 71:00


She Runs Eats Performs
FOOD FOR Snacks for Runners

She Runs Eats Performs

Play Episode Listen Later Jun 23, 2022 44:02


Today we are SPOTLIGHTING FOOD FOR …Snacks for Runners. We are going to talk about 1. How to use snacks strategically to support health and running 2. The Ideal Nutrient Composition of snacks pre, during and post running 3. Practicalities around being organised with snacks 4. Our favourite snacks and suggestions for you to try SHOW NOTES (01:01) How snacks may be used strategically for health and body composition goals as well as pre, during and post run fueling. We talk about the pitfalls of grazing and a reminder of the importance of adding in the energy value (calories) into your overall energy requirement calculations. (09:04) The Ideal Macronutrient Composition of snacks pre, during and post running. (11:31) The importance and timing of quick release carbohydrate foods pre and during training. (13:52) Karen's personal choices of quick release carbohydrate snacks (15:18) Post Recovery Snacks – what to eat within 30 minutes and what to eat 1-2 hours after your run. (24:55) Our favourite snack suggestions for you to try. (27:39) What ingredients Karen includes in her homemade bars and how she makes them so they don't crumble or break up when running! (32:28) Quick Release Snack Ideas for the 30-minute window at the end of a run and Aileen's post run recovery juice of watermelon, coconut water and honey. Plus, some easy snack meal ideas.  (39:47)  Key Take Aways  1.    Use snacks strategically for pre, during, post run fueling and recovery. 2.    Quick Release CHO snacks can support you to optimise glucose uptake and glycogen storage which will help keep your energy levels consistent during a long run and optimize recovery post run. 3.    Be aware of the additional Energy Intake from snacks in your overall Energy Intake Vs Energy Expenditure calculations but don't sacrifice these running snacks if your goal is weight loss – just be mindful and strategic in their use. 4.    POST RUN – have a QR CHO snack within 30 minutes and a larger snack or meal within 1-2 hours of a long run in the ratio of 4:1 CHO:Protein 5.    Finally remember to download our free guide TOP RUNNING SNACKS and Nutrient Timing. Related Topics: https://she-runs-eats-performs.captivate.fm/episode/food-for-pre-training (FOOD FOR ... PRE TRAINING) https://she-runs-eats-performs.captivate.fm/episode/food-for-during-training (FOOD FOR ... DURING TRAINING) https://she-runs-eats-performs.captivate.fm/episode/food-for-post-training (FOOD FOR ... POST TRAINING) Disclaimer: The suggestions we make during this episode are for guidance and advice only, and are not a substitute for medical advice or treatment. If you have any concerns regarding your health, please contact your healthcare professional for advice as soon as possible. Aileen Smith and Karen Campbell host https://my.captivate.fm/www.runnershealthhub.com (RUNNERS HEALTH HUB). A place for like-minded female runners who are looking for simple ways to support running performance, energy, endurance, and general great health. if this is your first time your show and you'd like to know more about us and She Runs Eats Performs please check out our https://she-runs-eats-performs.captivate.fm/episode/welcome-to-she-runs-eats-performs (TRAILER.) If you're ready to make learn more about how you may introduce easy nutrition into your running and training plan join our https://pay.hotmart.com/M38032672A?off=6nh9w023&checkoutMode=10 (Easy Nutrition For Healthy Runners Online Programme ) for short videos, recipes, downloads and LIVE training and Q&A. As a THANK YOU to you as one of our valued listeners, we have a special offer for you use COUPON CODE POD to get 33% discount off the full price which brings the price to £199. If you'd like help from Karen and Aileen to design a personalised sports nutrition plan for your running - please contact us at...

The Modern Therapist's Survival Guide with Curt Widhalm and Katie Vernoy
The Practicalities of Mental Health and Gender Affirming Care for Trans Youth: An Interview with Jordan Held, LCSW

The Modern Therapist's Survival Guide with Curt Widhalm and Katie Vernoy

Play Episode Listen Later Jun 20, 2022 46:47


The Practicalities of Mental Health and Gender Affirming Care for Trans Youth: An Interview with Jordan Held, LCSW Curt and Katie interview Jordan Held, LCSW, about gender affirming care, trans mental health, the practicalities of transition (as well as the different types of transition), specifics when working with trans youth, and the politicization of trans folks. We also explore culture and privilege related to transition. Transcripts for this episode will be available at mtsgpodcast.com! An Interview with Jordan Held, LCSW Jordan Held (he/him/his), LCSW is a Primary Therapist and Gender Specialist at Visions Adolescent Treatment Center. Prior to Visions, Jordan was a Therapist and Intake Coordinator at Children's Hospital Los Angeles in the Center for Trans Youth Health and Development, the largest trans youth health clinic in the USA. Jordan's mental health practice centers around creating a trauma-informed and healing-centered space for both adolescents and their families. Jordan's expertise is working with gender and sexual minority youth with complex histories of PTSD and trauma. Jordan speaks internationally about creating and supporting affirmative LGBTQ+ environments with an emphasis on informed consent and enhanced family communication. As a queer-identified, transgender man, Jordan brings an important dual perspective to his work as a mental health provider. Prior to social work, Jordan worked extensively in secondary school education, with a decade of experience teaching, coaching, and developing health and wellness curricula. Jordan's work focuses on gender violence prevention, diversity, equity, inclusion, and cultivating strength and belonging for teens. Jordan is on the Board of Directors of the Los Angeles LGBT Center, the Laurel Foundation, JQ International, and Mental Health America of Los Angeles. Jordan is also a long-time facilitator at Transforming Family, a support group for gender-diverse youth and their family. Jordan holds a Master of Social Welfare degree from UCLA, a Master of Sports Leadership degree from Northeastern University, and a Bachelor of Science in Kinesiology from the University of Connecticut. Jordan is an avid sneakerhead who self-cares by lifting heavy weights, going to the beach, loving his rescue dog, and embracing his gender euphoria!   In this podcast episode, we talk about trans mental health For Pride Month, we wanted to deepen our conversation on trans mental health and what therapists should know when working with trans individuals. What is gender-affirmative care? “Trans people are being used as political pawns.” – Jordan Held, LCSW The way that “gender affirming care” is being taken out of context What is actually happening, how it has been politicized The misinformation related to what is available to children who are exploring their gender (i.e., parental consent and youth care) The role of therapists versus the role of medical providers Discussion of gender norms Different types of transition for trans individuals Social transition (name, pronouns, clothes, haircut) Medical interventions that may start during puberty (i.e., puberty blockers, progesterone only birth control) Cross sex hormones and surgeries (which actually require a long process) States are very specific for what they require for gender care (as do insurance companies) Conversations in therapy for trans youth Gender journey Meeting the kids where they're at Lying to get what they need Letters and recommendations for surgery The gender dysphoria diagnosis and sorting that out from depression, anxiety, etc. Supporting trans youth with social transition and getting the support they need The concerns with maladaptive coping skills available online Positive resources for trans youth (scroll down to resources) Identity and impacts The Politicization of Trans Individuals “Shame on us as adults that we are so scared, we have so much fear over – let's be honest – what's in someone's pants, right? All of this has to do with the fear of something that we don't know. This fear… that somebody's genitals do not align what we think is in their pants. And as an adult talking to another adult, that's kind of gross, right? Like, why as adults do we care so much about what is in a kid's pants?” – Jordan Held, LCSW Jordan grew in privilege when he transitioned Legislation Schools removing conversations related to gender and sexuality Play and sports being withheld from trans kids Bias and how being trans is perceived The actual numbers of trans folks who want to play sports or want to use the bathroom that aligns with their gender identity Advice for trans kids and families where gender care is illegal, advice for therapists Age limits and laws that don't align with logic Culture, privilege, and being trans Increasing or decreasing privilege when one transitions Getting used to the changed dynamic within society based on external experience The complexity of the experience and the changing of the experience The concept of “passing” and how it taps into bias   Our Generous Sponsors for this episode of the Modern Therapist's Survival Guide: GreenOak Accounting  At GreenOak Accounting, they believe that every private practice should be profitable. They've worked with hundreds of practice owners across the country to have the financial confidence and information to make data-driven decisions. We want our client's businesses to be profitable so they can focus on fulfilling their mission. GreenOak Accounting specializes in working with therapists in private practice, and they have helped hundreds of therapists across the country reach their financial goals. They offer a number of monthly packages to fit a growing practice's needs - from bookkeeping to CFO services. Other specialized services include Profit First Support, compensation planning, and customized KPI Dashboards. They help therapists achieve their clinical goals by making sure they have a profitable practice, and offer unsurpassed support along the way. If you're interested in scheduling a complimentary consultation, please visit their website at www.GreenOakAccounting.com/consultation to learn more. Thrizer Thrizer is a new modern billing platform for therapists that was built on the belief that therapy should be accessible AND clinicians should earn what they are worth. Their platform automatically gets clients reimbursed by their insurance after every session. Just by billing your clients through Thrizer, you can potentially save them hundreds every month, with no extra work on your end. Every time you bill a client through Thrizer, an insurance claim is automatically generated and sent directly to the client's insurance. From there, Thrizer provides concierge support to ensure clients get their reimbursement quickly, directly into their bank account. By eliminating reimbursement by check, confusion around benefits, and obscurity with reimbursement status, they allow your clients to focus on what actually matters rather than worrying about their money. It is very quick to get set up and it works great in completement with EHR systems. Their team is super helpful and responsive, and the founder is actually a long-time therapy client who grew frustrated with his reimbursement times The best part is you don't need to give up your rate. They charge a standard 3% payment processing fee! Thrizer lets you become more accessible while remaining in complete control of your practice. A better experience for your clients during therapy means higher retention. Money won't be the reason they quit on therapy. Sign up using bit.ly/moderntherapists if you want to test Thrizer completely risk free! Sign up for Thrizer with code 'moderntherapists' for 1 month of no credit card fees or payment processing fees! That's right - you will get one month of no payment processing fees, meaning you earn 100% of your cash rate during that time.   Resources for Modern Therapists mentioned in this Podcast Episode: We've pulled together resources mentioned in this episode and put together some handy-dandy links. Please note that some of the links below may be affiliate links, so if you purchase after clicking below, we may get a little bit of cash in our pockets. We thank you in advance! Visions Adolescent Treatment Center Jordan Held's Website Jordan on Instagram WPATH Standards of Care   Online support and communities for trans youth: GLSEN The Trevor Project (helpline, suicidality) Human Rights Campaign (HRC) – Trans Resources HRC – LGBTQ+ Youth PFLAG Flamingo Rampant (publisher focusing on diversity, including gender diversity) Disclosure (Documentary) Google local universities in state – they often have support groups       Relevant Episodes of MTSG Podcast: Working with Trans Clients: Trans Resilience and Gender Euphoria – an interview with Beck Gee-Cohen Vulnerability, The News, and Your Clients: An interview with Dr. Abigail Weissman Additional episodes for Pride Month: Bi+ Erasure: An interview with Dr. Mimi Hoang, PhD Getting Personal to Advocate for Compassion, Understanding, and Social Justice: An interview with James Guay, LMFT   Who we are: Curt Widhalm, LMFT Curt Widhalm is in private practice in the Los Angeles area. He is the cofounder of the Therapy Reimagined conference, an Adjunct Professor at Pepperdine University and CSUN, a former Subject Matter Expert for the California Board of Behavioral Sciences, former CFO of the California Association of Marriage and Family Therapists, and a loving husband and father. He is 1/2 great person, 1/2 provocateur, and 1/2 geek, in that order. He dabbles in the dark art of making "dad jokes" and usually has a half-empty cup of coffee somewhere nearby. Learn more at: www.curtwidhalm.com Katie Vernoy, LMFT Katie Vernoy is a Licensed Marriage and Family Therapist, coach, and consultant supporting leaders, visionaries, executives, and helping professionals to create sustainable careers. Katie, with Curt, has developed workshops and a conference, Therapy Reimagined, to support therapists navigating through the modern challenges of this profession. Katie is also a former President of the California Association of Marriage and Family Therapists. In her spare time, Katie is secretly siphoning off Curt's youthful energy, so that she can take over the world. Learn more at: www.katievernoy.com A Quick Note: Our opinions are our own. We are only speaking for ourselves – except when we speak for each other, or over each other. We're working on it. Our guests are also only speaking for themselves and have their own opinions. We aren't trying to take their voice, and no one speaks for us either. Mostly because they don't want to, but hey. Stay in Touch with Curt, Katie, and the whole Therapy Reimagined #TherapyMovement: Patreon Buy Me A Coffee Podcast Homepage Therapy Reimagined Homepage Facebook Twitter Instagram YouTube   Consultation services with Curt Widhalm or Katie Vernoy: The Fifty-Minute Hour Connect with the Modern Therapist Community: Our Facebook Group – The Modern Therapists Group Modern Therapist's Survival Guide Creative Credits: Voice Over by DW McCann https://www.facebook.com/McCannDW/ Music by Crystal Grooms Mangano https://groomsymusic.com/

Unleash The Man Within
305 - Kutter Callaway on Why Theology and Psychology Work Well Together, Practicalities of Theology and Spiritual Applications Psychology in Recovery

Unleash The Man Within

Play Episode Listen Later Jun 16, 2022 62:54


Kutter Callaway (PhD, Fuller Theological Seminary) is associate professor of theology and culture at Fuller Theological Seminary and Co-Director of Reel Spirituality. He is the author of several books including Theology For Psychology & Counseling. Prior to teaching at Fuller, Callaway served in pastoral ministry for nearly a decade, focusing primarily on young and emerging adults. In today's interview, Kutter and Sathiya discuss why scientific research is not absolute, a healthy way for integrating theology and academia, and why good psychology will always enhance one's theology and vice versa. The interview ends with a segment where Sathiya poses a commonplace term like "community" and Kutter explains the concept through both a theological lens and then a psychological lens. This episode will provide you with a deeper understanding of why many practices in psychology have spiritual significance and some guidance on how to properly perceive academic research in a society that supremely values it. Learn more about Kutter Callaway Get a FREE copy of my bestselling book, The Last Relapse

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 91:12


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later May 30, 2022 65:01


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 30, 2022 91:16


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 30, 2022 65:01


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later May 30, 2022 91:16


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 91:12


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 64:50


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 64:50


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 91:12


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 30, 2022 91:16


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 30, 2022 65:01


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 64:50


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 91:12


Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 30, 2022 64:50


Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 25, 2022 86:55


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 25, 2022 86:59


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 25, 2022 86:59


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 25, 2022 86:55


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later May 25, 2022 86:59


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 25, 2022 86:55


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What's New and What You Need to Know and Do

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 25, 2022 86:55


Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 19, 2022 69:36


Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 69:01


Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 19, 2022 69:36


Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 69:01


Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later May 19, 2022 69:36


Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 19, 2022 69:01


Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

Redemptive Living Radio
#39: Rebuilding Trust - The Practicalities

Redemptive Living Radio

Play Episode Listen Later May 13, 2022 34:38


In this episode - we give a quick recap of episode #38 (since it's the foundation) and then dig into more of the practicalities of rebuilding trust.  Here are five things we focus on:   - It's the little things, not just the big ticket things that matter.   - Your personal positives can't outweigh the relational positives.   - Showing it's on your mind more than it's on hers.   - When it's the hardest it counts the most.   - Showing it's born out of your character change.   We are so glad YOU are here, thanks for joining us!   Click here to join the wait list for the Worthy of Her Trust Workshop. Click here to join the wait list for the RLW Retreat for women - releasing the next date and location soon! Would love to connect with you on Instagram - @shelley_martinkus.  We offer 1:1 coaching, couples recovery coaching, support groups, MasterClasses and on-line courses - check out our websites: redemptiveliving.com and rlforwomen.com for the full scoop!  Click here to subscribe to Shelley's {almost} monthly letter + announcements. Click here to subscribe to Jason's list.  Questions for the Podcast? Email us with the subject line: Podcast. 

Talking Talmud
Yevamot 61: The Saving Graces of the Priestly Marriage Practicalities

Talking Talmud

Play Episode Listen Later May 7, 2022 17:52 Very Popular


4 mishnayot! Practical details about kohanim and whom they can marry. For example, a kohen who is betrothed a widow, and is later appointed to be the kohen gadol, he's fine, they can marry. Plus, a story to make the point: R. Yehoshua ben Gamla. Also, how the kohen gadol cannot do yibum, only chalitzah. Also, the case of the aiylonit and the kohen gadol and the mitzvah of p'ru ur'vu. Plus, the kohen gadol is actually not supposed to marry too young of a girl. Also, a man may not disregard the mitzvah of being fruitful and multiplying when he gets married - unless he already has children. The details of which, are of course, disputed by Beit Hillel and Beit Shammai.

Ancestral Kitchen
# 30 - The Whole Chicken & Nothing But The Chicken

Ancestral Kitchen

Play Episode Listen Later Apr 25, 2022 52:35


"A whole chicken is one of the most economical things you can bring into your kitchen" Jamie Waldron, Butcher The chicken, the whole chicken, and nothing but the chicken! Pasture-raised, ethical meat is a popular catch-phrase nowadays, but can it really be affordable? In this episode we will show you that it is, and how becoming fluent in "whole chicken" will make your meals more nutritious, delicious, easy AND budget-friendly. We'll also bust a few chicken myths and share how we utilize whole chickens - including the odd bits - in our kitchens! Love what we're doing and want to access to our library of audio, video and downloadable extra content? Our podcast is sponsored by our patrons and listeners who also are supported by the extra content that we share over at our http://patreon.com/ancestralkitchenpodcast (Patreon community!) For $9 a month (or equivalent in your currency) you'll be helping us with the costs of recording, editing and putting this work into the world. And you'll get to be part of our world on a deeper level - we've got a monthly intimate patron-exclusive podcast called Kitchen Table Chats and we also share cooking classes, extra interviews and much more. Check out http://patreon.com/ancestralkitchenpodcast (www.patreon.com/ancestralkitchenpodcast) for all the details! Here's what we cover: 0:00-5:20 Intro, what we last ate and welcome new patreon community member 5:20-15:00 Chicken price comparison organic/conventional in UK and US; astounding difference in whole chicken/breast price, challenges of organic certification "Whole chickens and supermarket chicken breasts are incomparable in terms of both nutrition and cost" 15:00-24:00 Nutritional content, craziness of industrial animal raising and what do we (and should we) feed chickens "Give a store label 0% of your trust" 24:00 onwards: Practicalities in the kitchen "I love the idea of freezing shredded chicken in stock" 25:00 -29:00 How to cut up a whole chicken before cooking, including information on the Patreon chicken video! 29:00-38:50 Cooking a whole chicken 38:50-49:45 The 'extra bits': Head, feet, neck and broth, including the value of broth obtained from a whole chicken "$72 of broth from one single whole chicken" 49:45 How Andrea uses her chicken meat Resources Mentioned: http://instagram.com/valledelsasso (Flavio) is Alison's farmer https://ancestralkitchen.com/2022/03/01/26-bones-water-the-magic-of-stock/ (Our stock episode ) http://pipersfarm.co.uk (Piper's Farm in the UK ) http://polyfacefarms.com (Polyface Farm )(Joel Salatin's farm) http://patreon.com/ancestralkitchenpodcast (To access our Patreon video on an alternative way of cutting up a whole chicken which divides the meat equally between each portion) https://www.jwaldronbutchers.com/who-am-i (Jamie Waldron ) https://youtu.be/2z7KU7WHr3M (Jamie Waldron parting a chicken video) - notice in the video the original butcher left the chicken butt ON and just cut the gland OUT. At the end he does a demo without any background talking. https://amzn.to/37IOa9X (Home Butchering Handbook: Enjoy Finer, Fresher, Healthier Cuts of Meat from Your Own Kitchen (A Living Free Guide) by Jamie Waldron) https://youtu.be/OEu_ZmLJTm8 (Another way to cut the whole chicken, including backbone). Doesn't evenly portion meat, though. "Get to know your farmer, build a relationship - don't pay attention to something stamped on a label on a supermarket shelf" Additional Resources Not Mentioned: If you are ready to deep dive into chickens, this trio of books will set you off and running: https://polyfaceyum.com/product-cat/cart/#!/YOUR-SUCCESSFUL-FARM-BUSINESS/p/171059408 (Your Successful Farm Business by Joel Salatin) (yes - non-farmers should be reading this, too. If you are ready to explore the ideas of redemptive farming, this book will open up an entire universe. It will pack in way more than you expect!)...

10 Percent True - Tales from the Cockpit
Bringing the F-15E Strike Eagle to the Air Force: "Junior" Suminsby, F-15E Initial Cadre

10 Percent True - Tales from the Cockpit

Play Episode Listen Later Mar 4, 2022 151:57 Very Popular


F-15E Strike Eagle Enters Service - "Junior" Suminsby, F-15E Initial Cadre Tip Jar: https://www.paypal.com/donate/?hosted_button_id=GDJU6CM3GWZTNDiscussion on Discord: https://discord.gg/9vJ3hPYFQh10PCT #30: Rob "Junior" Suminsby.00:00:00 Introduction    00:01:55 Junior's Bio    00:03:07 F-15E Initial Cadre Selection  00:05:05 Patch Wearers Galore    00:06:21 '791 and the DRF    00:08:08 A Cadre and B Cadre    00:09:44 Flying the F-15 & F-16    00:13:33 Strike Eagle Requirements and Timing 00:18:39 Initial Cadre Composition   00:22:48 Academics with McAir    00:28:53 No CFTs    00:33:53 Cockpit Avionics    00:36:30 Radar Mapping    00:40:29 Tactics Development    00:45:47 Stuff Engineers Think Up   00:52:59 Responsibilities of the Initial Cadre 00:58:58 Cooks vs. Chefs    01:01:14 Tactics Validation    01:07:44 Boil the Ocean?    01:18:15 Community Perspectives    01:19:52 Light Grey Handling Differences  01:24:26 G Limits     01:25:13 Back Seat Controls    01:29:21 First Operational Wing - 4th TFW  01:34:02 Practicalities of a Dual Role Mission 01:38:49 LANTIRN    01:45:03 Scenarios    01:47:48 Training Syllabus    01:50:06 North Pointer... Software Development 01:53:55 WSO integration    01:57:24 Challenges of New Capabilities   02:00:31 Degraded Operations    02:05:54 AGMs     02:09:32 Outboard Pylons    02:11:05 Learning Outcomes    02:25:08 Sending the First Students off to WarSupport the show (https://www.paypal.com/donate?hosted_button_id=GDJU6CM3GWZTN)